MANKIND PHARMA LIMITED
Latest filings
- Mankind Pharma outlines FY30 growth, debt reduction and ACTx plans · Investor Communications
- Q2 and H1 FY27 profit rises sharply on strong revenue growth · Compliance
- Mankind Pharma shares Q2 and H1 FY27 earnings call recording · Investor Communications
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical formulations across chronic, acute, and consumer healthcare categories in India, with an international business run through its wholly owned subsidiary Bharat Serums and Vaccines (BSV). Domestic formulations span cardiac, anti-diabetic, anti-infective and other therapy areas, while consumer healthcare covers OTC brands such as Manforce and Gasofast. The international business posted ₹605 cr in Q1 FY27 (+29% YoY) with BSV contributing to high-teens growth, and BSV holds 100% market share in anti-D in India. Consumer healthcare generated ₹246 cr in Q1 FY27, partly hit by discontinued cash-and-carry distribution. Q1 FY27 consolidated revenue was ₹4,031 cr (+13% YoY) and PAT was ₹574 cr (+29% YoY); FY26 revenue was ₹14,277.64 cr with EBITDA margin of 26.94%. Costs are dominated by employees (22.3% of revenue) and other operating expenses (24%), with materials at 16%, depreciation 6.2% and capex 4.4% of revenue.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from MANKIND PHARMA LIMITED's filed financials and exchange disclosures
What does MANKIND PHARMA LIMITED do?
MANKIND PHARMA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol MANKIND.
Is MANKIND PHARMA LIMITED profitable?
Yes. Over the trailing twelve months MANKIND PHARMA LIMITED reported a net profit of ₹2,068 Cr on revenue of ₹14,738 Cr.
Does MANKIND PHARMA LIMITED pay a dividend?
Yes. The dividend yield is 0.04% at the current price. It paid out 2% of its profit as dividend in FY26.
Is MANKIND PHARMA LIMITED debt-free?
No. It reported borrowings of ₹6,312 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹5,920 Cr after cash. Debt stands at 0.38× equity. That is higher than 73% of its 166 Pharmaceuticals peers.
Is MANKIND PHARMA LIMITED expensive compared with its peers?
On trailing P/E, MANKIND PHARMA LIMITED ranks 117 of 158 in Pharmaceuticals — cheaper than 26% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.
How much does the MANKIND PHARMA LIMITED share price move in a day?
On a typical session MANKIND PHARMA LIMITED moves 0.98% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track MANKIND PHARMA LIMITED's announcements?
Every NSE and BSE filing by MANKIND PHARMA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.